Điều trị Liraglutide cải thiện vi tuần hoàn vành ở chuột Zucker béo phì kháng Insulin trên chế độ ăn mặn
Tóm tắt
Béo phì, tăng huyết áp và tiền đái tháo đường đóng góp lớn vào bệnh động mạch vành, suy tim và các biến cố mạch máu, và là nguyên nhân chính gây tử vong và bệnh tật trong các xã hội phát triển. Nhạy cảm với muối làm trầm trọng thêm rối loạn chức năng nội mô. Trong nghiên cứu này, chúng tôi đã điều tra tác động của việc kích hoạt thụ thể peptide giống glucagon-1 (GLP-1) mạn tính lên vi tuần hoàn vành và tái tạo tim trong chuột Zucker trên chế độ ăn nhiều muối (6% NaCl).
Các con chuột Zucker gầy (+/+) và béo phì (fa/fa) 8 tuần tuổi được điều trị bằng dung dịch hoặc liraglutide (LIRA) (0,1 mg/kg/ngày, tiêm dưới da) trong 8 tuần. Huyết áp tâm thu (SBP) được đo bằng phương pháp vòng đuôi ở chuột tỉnh. Chức năng cơ tim được đánh giá bằng siêu âm tim. Kỹ thuật vi mạch tương phản đồng bộ được sử dụng để điều tra chức năng mạch vành (mạch có đường kính trong 50–350 µm) in vivo trên chuột đã gây mê. Mức độ biểu hiện gen và protein của các yếu tố vasoactive, dấu hiệu viêm, căng thẳng oxy hóa và tái tạo được xác định bằng PCR thời gian thực và phương pháp Western blot.
Từ khóa
#Béo phì; Peptide giống glucagon-1; Vi tuần hoàn vành; Điều trị Liraglutide; Chuột ZuckerTài liệu tham khảo
Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vasc Pharmacol. 2006;45(5):268–76.
Virdis A, Neves MF, Duranti E, Bernini G, Taddei S. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des. 2013;19(13):2382–9.
Bagi Z, Broskova Z, Feher A. Obesity and coronary microvascular disease—implications for adipose tissue-mediated remote inflammatory response. Curr Vasc Pharmacol. 2014;12(3):453–61.
Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567–76.
Zhu J, Huang T, Lombard JH. Effect of high-salt diet on vascular relaxation and oxidative stress in mesenteric resistance arteries. J Vasc Res. 2007;44:382–90.
Maruyama K, Kagota S, Van Vliet BN, Wakuda H, Shinozuka K. A maternal high salt diet disturbs cardiac and vascular function of offspring. Life Sci. 2015;136:42–51.
Nurkiewicz TR, Boegehold MA. High salt intake reduces endothelium dependent dilation of mouse arterioles via superoxide anion generated from nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1550–6.
Ying WZ, Aaron KJ, Sanders PW. Transforming growth factor-β regulates endothelial function during high salt intake in rats. Hypertension. 2013;62:951–6.
Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park JK, Luft FC, Mervaala EM. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension. 2001;37(2 Pt 2):433–9.
Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, Holz GG. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol. 2011;107(2):236–47.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther. 2018;9:2383–92.
Chen XM, Zhang WQ, Tian Y, Wang LF, Chen CC, Qiu CM. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. Cardiovasc Diabetol. 2018;17:53.
Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127:74–85.
Langlois A, Dal S, Vivot K, Mura C, Seyfritz E, Bietiger W, Dollinger C, Peronet C, Maillard E, Pinget M, Jeandidier N, Sigrist S. Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties. Br J Pharmacol. 2016;173(24):3443–53.
Zhang WQ, Tian Y, Chen XM, Wang LF, Chen CC, Qiu CM. Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes. Diabetol Metab Syndr. 2018;10:91.
Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 2013;62(5):1697–708.
Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW, Basu A, Liu Z. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci. 2014;127(3):163–70.
Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015;14:41.
Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.
Sukumaran V, Tsuchimochi H, Sonobe T, Shirai M, Pearson JT. Liraglutide improves renal endothelial function in obese Zucker rats on a high-salt diet. J Pharmacol Exp Ther. 2019;369(3):375–88.
Scarfe L, Schock-Kusch D, Ressel L, Friedemann J, Shulhevich Y, Murray P, Wilm B, de Caestecker M. Transdermal measurement of glomerular filtration rate in mice. J Vis Exp. 2018;140:e58520.
Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Pearson JT. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade. Biochem Pharmacol. 2017;144:90–9.
Pearson JT, Yoshimoto M, Chen YC, Sultani R, Edgley AJ, Nakaoka H, Nishida M, Umetani K, Waddingham MT, Jin HL, Zhang Y, Kelly DJ, Schwenke DO, Inagaki T, Tsuchimochi H, Komuro I, Yamashita S, Shirai M. Widespread coronary dysfunction in the absence of HDL receptor SR-B1 in an ischemic cardiomyopathy mouse model. Sci Rep. 2017;7(1):18108.
Feher A, Broskova Z, Bagi Z. Age-related impairment of conducted dilation in human coronary arterioles. Am J Physiol Heart Circ Physiol. 2014;306:H1595–601.
Luo L, Liu D, Tang C, Du J, Liu AD, Holmberg L, Jin H. Sulfur dioxide upregulates the inhibited endogenous hydrogen sulfide pathway in rats with pulmonary hypertension induced by high pulmonary blood flow. Biochem Biophys Res Commun. 2013;433:519–25.
Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y. Telmisartan, an angiotensin II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res. 2010;33(7):695–702.
Mak GS, Sawaya H, Khan AM, Arora P, Martinez A, Ryan A, Emande L, Newton-Cheh C, Wang TJ, Scherrer-Crosbie M. Effects of subacute dietary salt intake and acute volume expansion on diastolic function in young normotensive individuals. Eur Heart J Cardiovasc Imaging. 2013;14:1092–8.
Katayama IA, Pereira RC, Dopona EP, Shimizu MH, Furukawa LN, Oliveira IB, Heimann JC. High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation. J Nutr. 2014;144:1571–8.
Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens. 2012;14(4):198–205.
Lobato NS, Filgueira FP, Prakash R, Giachini FR, Ergul A, Carvalho MH, Webb RC, Tostes RC, Fortes ZB. Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS ONE. 2013;8(5):e63449.
Schach C, Resch M, Schmid PM, Riegger GA, Endemann DH. Type 2 diabetes: increased expression and contribution of IKCa channels to vasodilation in small mesenteric arteries of ZDF rats. Am J Physiol Heart Circ Physiol. 2014;307(8):H1093–102.
Kushima H, Mori Y, Koshibu M, Hiromura M, Kohashi K, Terasaki M, Fukui T, Hirano T. The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovasc Diabetol. 2017;16(1):122.
Aung MM, Slade K, Freeman LAR, Kos K, Whatmore JL, Shore AC, Gooding KM. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes. Diabetologia. 2019;62:1701–11.
Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221:375–82.
Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, Hecksher-Sørensen J, Ingvorsen C, Polex-Wolf J, Knudsen LB. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE−/− and LDLr−/−mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844–57.
Koshibu M, Mori Y, Saito T, Kushima H, Hiromura M, Terasaki M, Takada M, Fukui T, Hirano T. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. Am J Physiol Endocrinol Metab. 2019;316(5):E895–907.
Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, Yao YH, Ma CY, Zhu CG, Guo YL, Wu NQ, Sun J, Chen BX, Li JJ. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17(1):48.
Gao M, Deng XL, Liu ZH, Song HJ, Zheng J, Cui ZH, Xiao KL, Chen LL, Li HQ. Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats. J Diabetes Complicat. 2018;32:985–94.
Bretón-Romero R, Weisbrod RM, Feng B, Holbrook M, Ko D, Stathos MM, Zhang JY, Fetterman JL, Hamburg NM. Liraglutide treatment reduces endothelial endoplasmic reticulum stress and insulin resistance in patients with diabetes mellitus. J Am Heart Assoc. 2018;7(18):e009379.
Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N, Takayanagi R. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012;61(10):1422–34.
Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2017;57(3):464–73.
Katakam PV, Tulbert CD, Snipes JA, Erdös B, Miller AW, Busija DW. Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species. Am J Physiol Heart Circ Physiol. 2005;288(2):H854–60.
Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D, Takayanagi R. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis. 2015;240(1):250–9.
Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37.
Li W, Cui M, Wei Y, Kong X, Tang L, Xu D. Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem. 2012;30:749–57.
Gao F, Han ZQ, Zhou X, Shi R, Dong Y, Jiang TM, Li YM. High-salt intake accelerated cardiac remodeling in spontaneously hypertension rats: time window of left ventricular functional transition and its relation to salt-loading doses. Clin Exp Hypertens. 2011;33:492–9.
Wu H, Chen L, Xie J, Li R, Li GN, Chen QH, Zhang XL, Kang LN, Xu B. Periostin expression induced by oxidative stress contributes to myocardial fibrosis in a rat model of high salt-induced hypertension. Mol Med Rep. 2016;14:776–82.